FibroBiologics, Inc. (FBLG) entered into a securities purchase agreement with Hamid Khoja, Ph.D., the company's Chief Scientific Officer, on September 15, 2026. The agreement outlines a private placement intended to raise capital through the issuance of common stock and accompanying warrants.
Under the terms of the agreement, the Company will sell 298,508 shares of common stock and warrants to purchase an equal number of shares. The offering price for both the shares and the warrants is set at $1.675 per unit. This price is calculated as the consolidated closing bid price of the Company's common stock on The Nasdaq Capital Market on September 14, 2026, which was $1.55 per share, plus an additional $0.125 per warrant.
The Company expects to receive gross proceeds of approximately $0.5 million from the transaction, before deducting estimated offering expenses. The filing indicates that the net proceeds will be used for general corporate purposes and working capital. The transaction is expected to close on September 15, 2026, subject to the satisfaction of customary closing conditions.
The accompanying warrants allow the holder to purchase up to 298,508 shares of common stock at an exercise price of $1.55 per share. These warrants are exercisable at any time following the issuance date and will expire on the five-year anniversary of that date. The warrants include cashless exercise provisions and standard anti-dilution adjustments for stock splits, stock dividends, rights offerings, and pro rata distributions.
The sale of these securities is being conducted pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D. Consequently, the securities are not registered and may not be offered or sold in the United States except under an effective registration statement or an applicable exemption.
